Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
TriSalus Life Sciences Inc. (TLSIW)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
11/12/2025: TLSIW (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -54.53% | Avg. Invested days 31 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 11/12/2025 |
Key Highlights
Company Size ETF | Market Capitalization 0 USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta 0.47 | 52 Weeks Range 0.42 - 2.25 | Updated Date 06/10/2025 |
52 Weeks Range 0.42 - 2.25 | Updated Date 06/10/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) - |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -84.67% | Operating Margin (TTM) -79.95% |
Management Effectiveness
Return on Assets (TTM) -85.52% | Return on Equity (TTM) - |
Valuation
Trailing PE - | Forward PE - | Enterprise Value - | Price to Sales(TTM) - |
Enterprise Value - | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding - | Shares Floating 29370602 |
Shares Outstanding - | Shares Floating 29370602 | ||
Percent Insiders - | Percent Institutions - |
Upturn AI SWOT
TriSalus Life Sciences Inc.
Company Overview
History and Background
TriSalus Life Sciences, Inc. focuses on developing and commercializing innovative technologies to address unmet needs in liver-directed cancer care. While specifics on its founding year and detailed historical milestones are limited in readily available public sources, the company has emerged as a player in the interventional oncology space.
Core Business Areas
- Drug Delivery Systems: Develops and markets drug delivery systems designed to improve the efficacy and safety of cancer treatments directly to liver tumors.
- Immunotherapy: Focuses on the development of immunotherapies delivered directly to tumors in the liver.
Leadership and Structure
Information on the detailed organizational structure and leadership team is not readily available in the public domain. Refer to the TriSalus Life Sciences' official website or SEC filings for detailed information.
Top Products and Market Share
Key Offerings
- TriNav Infusion System: A pressure-enabled drug delivery system designed to enhance the intra-tumoral delivery of therapeutics. Specific market share data is not publicly available. Competitors include Merit Medical Systems (MMSI), Boston Scientific (BSX), and Cook Medical which offer similar targeted drug delivery devices.
Market Dynamics
Industry Overview
The interventional oncology market is growing, driven by increasing cancer incidence and demand for minimally invasive treatments. The sector is driven by advances in targeted therapies and drug delivery systems.
Positioning
TriSalus Life Sciences is positioned as an innovator in the drug delivery space for liver-directed cancer treatments. Its pressure-enabled technology differentiates it from standard infusion techniques.
Total Addressable Market (TAM)
The total addressable market for liver cancer treatments is estimated to be in the billions of dollars, encompassing various therapies including surgery, ablation, and systemic treatments. TriSalus is positioned to capture a segment of this market through its drug delivery technology, with potential for growth as it expands its product offerings.
Upturn SWOT Analysis
Strengths
- Innovative pressure-enabled drug delivery technology
- Focus on liver-directed cancer therapy
- Potential for improved treatment efficacy and safety
- Early mover advantage in a niche market segment
Weaknesses
- Limited publicly available financial information
- Dependence on the success of its proprietary technology
- Potential regulatory hurdles for new products
- Competition from established medical device companies
Opportunities
- Expansion of product portfolio to include additional therapies
- Partnerships with pharmaceutical companies to develop combination therapies
- Geographic expansion into new markets
- Potential for acquisition by a larger medical device or pharmaceutical company
Threats
- Competition from alternative cancer treatments
- Changes in reimbursement policies
- Product liability risks
- Economic downturn impacting healthcare spending
Competitors and Market Share
Key Competitors
- MMSI
- BSX
- COOK MEDICAL
Competitive Landscape
TriSalus Life Sciences' competitive advantage lies in its innovative pressure-enabled drug delivery technology, which may offer improved treatment efficacy compared to standard infusion techniques. However, it faces competition from larger, more established medical device companies with broader product portfolios and greater market reach.
Growth Trajectory and Initiatives
Historical Growth: Historical growth trends are not available due to limited publicly available financial data.
Future Projections: Future growth projections are not available due to limited analyst coverage and public financial data.
Recent Initiatives: Information on recent strategic initiatives is not readily available. Refer to the TriSalus Life Sciences' official website or SEC filings for detailed information.
Summary
TriSalus Life Sciences is an emerging player in the liver-directed cancer therapy space with a promising drug delivery technology. Its success hinges on the adoption and efficacy of its TriNav system. The company faces competition from larger medical device companies and the need to navigate regulatory hurdles. Access to funding and strategic partnerships will be vital for its long-term growth.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Industry Reports
Disclaimers:
The information provided is based on publicly available sources and is for informational purposes only. It does not constitute financial advice. Market share data is estimated and may not be precise. Consult a qualified financial advisor before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About TriSalus Life Sciences Inc.
Exchange NASDAQ | Headquaters Westminster, CO, United States | ||
IPO Launch date 2023-08-11 | CEO, President & Director Ms. Mary T. Szela B.S.N., M.B.A. | ||
Sector Healthcare | Industry Medical Devices | Full time employees 110 | Website https://trisaluslifesci.com |
Full time employees 110 | Website https://trisaluslifesci.com | ||
TriSalus Life Sciences, Inc. engages in the research, development, and commercialization of drug delivery technology platform and immuno-oncology therapeutics to improve outcomes for patients with difficult-to-treat liver and pancreatic cancers. It offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial for treating locally advanced pancreatic cancer. The company is also developing nelitolimod, an investigational immunotherapeutic in Phase 1 clinical trial for the treatment of uveal melanoma, intrahepatic cholangiocarcinoma, hepatocellular carcinoma, and pancreatic cancer. It serves interventional radiologists, IR technicians, medical oncologists, nursing support, value analysis committee staff, and patients through its sales representatives and sales managers. The company was founded in 2009 and is headquartered in Westminster, Colorado.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.